Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Commercial Speech Restrictions Could Hold Up In Court, Agency Says

Executive Summary

FDA could still enforce restrictions on commercial speech even in light of the recent Supreme Court decision striking down limits on pharmacy advertising of compounding, FDA Associate Chief Counsel Patricia Kaeding said

You may also be interested in...



Ads For New Drugs Would Require FDA Preclearance Under Rx Safety Bill

Promotional materials for recently-approved drugs would receive special scrutiny by the Center for Postmarket Drug Evaluation & Research proposed in Senate legislation

Ads For New Drugs Would Require FDA Preclearance Under Rx Safety Bill

Promotional materials for recently-approved drugs would receive special scrutiny by the Center for Postmarket Drug Evaluation & Research proposed in Senate legislation

DTC Ads Should Cite Range Of Treatment Options, Blue Cross Assoc. Tells FDA

Direct-to-consumer advertising should include disclosures to note when a particular drug is one of a range of available treatment choices, the Blue Cross and Blue Shield Association said in comments to FDA

Related Content

UsernamePublicRestriction

Register

PS040298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel